Wednesday, 22 May 2019

Pfizer's Herceptin biosimilar approved in Europe

31 July 2018 | News

Trazimera is the third biosimilar version of Roche's Herceptin in Europe.

Singapore – The European Commission approves Pfizer's TRAZIMERA, a biosimilar of Roche's cancer med Herceptin (trastuzumab).

TRAZIMERA, a potential biosimilar to Herceptin (trastuzumab), targets the treatment of HER2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

The advisory group CHMP adopted a positive opinion backing approval in May.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Will stem cell therapy market witness highest growth in Asia by 2020?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls